Cargando…
Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis
BACKGROUND: The taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification includes classic, endemic, epidemic/HIV associated and iatrogenic KS, and KS i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142155/ https://www.ncbi.nlm.nih.gov/pubmed/37106396 http://dx.doi.org/10.1186/s12967-023-04130-6 |
_version_ | 1785033547094949888 |
---|---|
author | Openshaw, M. R. Gervasi, E. Fulgenzi, C. A. M. Pinato, D. J. Dalla Pria, A. Bower, M. |
author_facet | Openshaw, M. R. Gervasi, E. Fulgenzi, C. A. M. Pinato, D. J. Dalla Pria, A. Bower, M. |
author_sort | Openshaw, M. R. |
collection | PubMed |
description | BACKGROUND: The taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification includes classic, endemic, epidemic/HIV associated and iatrogenic KS, and KS in men who have sex with men (MSM). We assessed the medical relevance of the current classification of KS and sought clinically useful improvements in KS taxonomy. METHODS: We reviewed the demographic and clinicopathological features of 676 patients with KS, who were referred to the national centre for HIV oncology at Chelsea Westminster hospital between 2000 and 2021. RESULTS: Demographic differences between the different subtypes of KS exist as tautological findings of the current classification system. However, no definitive differences in clinicopathological, virological or immunological parameters at presentation could be demonstrated between the classic, endemic or MSM KS patients. Reclassifying patients as either immunosuppressed or non-immunosuppressed, showed that the immunosuppressed group had a significantly higher proportion of adverse disease features at presentation including visceral disease and extensive oral involvement, classified together as advanced disease (chi(2) P = 0.0012*) and disseminated skin involvement (chi(2) P < 0.0001*). Immunosuppressed patients had lower CD4 counts, higher CD8 counts and a trend towards higher HHV8 levels compared to non-immunosuppressed patients, however overall survival and disease specific (KS) survival was similar across groups. CONCLUSION: The current system of KS classification does not reflect meaningful differences in clinicopathological presentation or disease pathogenesis. Reclassification of patients based on the presence or absence of immunosuppression is a more clinically meaningful system that may influence therapeutic approaches to KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04130-6. |
format | Online Article Text |
id | pubmed-10142155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101421552023-04-29 Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis Openshaw, M. R. Gervasi, E. Fulgenzi, C. A. M. Pinato, D. J. Dalla Pria, A. Bower, M. J Transl Med Research BACKGROUND: The taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification includes classic, endemic, epidemic/HIV associated and iatrogenic KS, and KS in men who have sex with men (MSM). We assessed the medical relevance of the current classification of KS and sought clinically useful improvements in KS taxonomy. METHODS: We reviewed the demographic and clinicopathological features of 676 patients with KS, who were referred to the national centre for HIV oncology at Chelsea Westminster hospital between 2000 and 2021. RESULTS: Demographic differences between the different subtypes of KS exist as tautological findings of the current classification system. However, no definitive differences in clinicopathological, virological or immunological parameters at presentation could be demonstrated between the classic, endemic or MSM KS patients. Reclassifying patients as either immunosuppressed or non-immunosuppressed, showed that the immunosuppressed group had a significantly higher proportion of adverse disease features at presentation including visceral disease and extensive oral involvement, classified together as advanced disease (chi(2) P = 0.0012*) and disseminated skin involvement (chi(2) P < 0.0001*). Immunosuppressed patients had lower CD4 counts, higher CD8 counts and a trend towards higher HHV8 levels compared to non-immunosuppressed patients, however overall survival and disease specific (KS) survival was similar across groups. CONCLUSION: The current system of KS classification does not reflect meaningful differences in clinicopathological presentation or disease pathogenesis. Reclassification of patients based on the presence or absence of immunosuppression is a more clinically meaningful system that may influence therapeutic approaches to KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04130-6. BioMed Central 2023-04-27 /pmc/articles/PMC10142155/ /pubmed/37106396 http://dx.doi.org/10.1186/s12967-023-04130-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Openshaw, M. R. Gervasi, E. Fulgenzi, C. A. M. Pinato, D. J. Dalla Pria, A. Bower, M. Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis |
title | Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis |
title_full | Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis |
title_fullStr | Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis |
title_full_unstemmed | Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis |
title_short | Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis |
title_sort | taxonomic reclassification of kaposi sarcoma identifies disease entities with distinct immunopathogenesis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142155/ https://www.ncbi.nlm.nih.gov/pubmed/37106396 http://dx.doi.org/10.1186/s12967-023-04130-6 |
work_keys_str_mv | AT openshawmr taxonomicreclassificationofkaposisarcomaidentifiesdiseaseentitieswithdistinctimmunopathogenesis AT gervasie taxonomicreclassificationofkaposisarcomaidentifiesdiseaseentitieswithdistinctimmunopathogenesis AT fulgenzicam taxonomicreclassificationofkaposisarcomaidentifiesdiseaseentitieswithdistinctimmunopathogenesis AT pinatodj taxonomicreclassificationofkaposisarcomaidentifiesdiseaseentitieswithdistinctimmunopathogenesis AT dallapriaa taxonomicreclassificationofkaposisarcomaidentifiesdiseaseentitieswithdistinctimmunopathogenesis AT bowerm taxonomicreclassificationofkaposisarcomaidentifiesdiseaseentitieswithdistinctimmunopathogenesis |